Research programme: GPCR-targeting biotherapeutics - MorphoSys/G7 Therapeutics

Drug Profile

Research programme: GPCR-targeting biotherapeutics - MorphoSys/G7 Therapeutics

Latest Information Update: 02 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G7 Therapeutics; MorphoSys
  • Developer MorphoSys
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 30 Nov 2016 Heptares signs a share purchase agreement for the 100% acquisition in G7 Therapeutics
  • 29 Nov 2016 Heptares Therapeutics plans to acquire G7 Therapeutics
  • 04 Aug 2015 MorphoSys and G7 Therapeutics agree to co-develop GPCR-targeting antibodies in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top